Article · 9 Feb 2026
Conference abstractPublished 11 Jul 2016
GLP-1 receptor agonist exacerbates mucus hyper secretory phenotype in βENaC-transgenic mouse with obstructive lung diseases
Kumamoto University, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic obstructive pulmonary disease (COPD) is mainly characterized by airway mucus obstruction, chronic infl ammation and emphysema. Identifi cation of novel factors that control the COPD pulmonary phenotypes is an important issue for better treatment of COPD patients. Glucagon like peptide-1 (GLP-1) is a gastrointestinal hormone and because of its pancreatic supporting function, GLP-1 receptor agonist is clinically used as a drug for the treatment of type-2 diabetes. Interestingly, GLP-1 receptor is highly expressed in lung tissue compared with other tissues. But little is known about the physiological and pathophysiological roles of GLP-1 in lung. Here, we showed that intratracheal treatment of airway specifi c Ã?²ENaC (epithelial Na+ channel Ã?² subunit)- transgenic mice, a murine model of COPD that basically exhibits airway mucus obstruction with GLP-1 receptor agonist Exendin-4 (10 pmol/day, 2 weeks) signifi cantly up regulates mucin gene expression in lung tissue. Moreover, Exendin-4 signifi cantly increased the alveolar mean linear intercept (MLI), a measure of emphysema in Ã?²ENaC-Tg mice. Notably, GLP-1 receptor agonist (Exendin-4 and Liraglutide) treatment (0.1 nM, 6-12 hours) also enhanced mucin expression in Ã?²/Ã?³ENaC-over expressing 16HBE14o-cells and the eff ect was possibly induced by p38 MAP kinase pathway. Despite observations of Exendin-4-dependent mucin up regulation in WT mice and parental 16HBE14o cells, exacerbation of pulmonary phenotypes was not observed in these conditions. Together, our studies demonstrate that pulmonary GLP-1 signal exacerbates the phenotypes of Ã?²ENaC-Tg mice at least partly viap38MAPKdependent mucin induction and our data may caution against the clinical use of inhaled GLP-1 receptor agonist in COPD patients with type-2 diabetes.
Subjects
Pulmonology & RespiratoryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pulmonary & Respiratory Medicine.
Commentary · 29 Dec 2025
Evolving IPF: Personalized Therapies, Future Directions
Brief report · 29 Dec 2025
PH/PAH: Advancements, Guidelines, Future Directions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPulmonary & Respiratory Medicine
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Hirofumi Nohara”
- BylineArticles whose byline prints “Tsuyoshi Shuto”
- BylineArticles whose byline prints “Ryunosuke Nakashima”
- BylineArticles whose byline prints “Shunsuke Kamei”
- BylineArticles whose byline prints “Haruka Fujikawa”
- BylineArticles whose byline prints “Kasumi Maruta”
- BylineArticles whose byline prints “Mary Ann Suico”
- BylineArticles whose byline prints “Hirofumi Kai”
